Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2024-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Announces-Positive-Results-from-its-Phase-II-Exploratory-STARGAZE-Trial-of-Apraglutide-in-Patients-with-Steroid-Refractory-Gastrointestinal-Acute-Graft-versus-Host-Disease-SR-GI-aGVHD/default.aspx
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Announces-Positive-Topline-Results-from-Global-Phase-III-Trial-of-Once-Weekly-Apraglutide-in-Adults-with-Short-Bowel-Syndrome-with-Intestinal-Failure-SBS-IF/default.aspx
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Present-Four-Abstracts-at-the-ASPEN-2024-Nutrition-Science–Practice-Conference/default.aspx
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Results-Achieves-2023-Financial-Guidance/default.aspx
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2023-Investor-Update-Call/default.aspx
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Announces-Publication-in-The-Lancet-Gastroenterology–Hepatology-of-New-Linaclotide-Phase-III-Data-in-Children-and-Adolescents-Aged-6-17-Years-with-Functional-Constipation/default.aspx
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Maintains-FY-2023-Financial-Guidance-and-Announces-FY-2024-Financial-Guidance/default.aspx
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Present-at-the-42nd-Annual-J.P.-Morgan-Healthcare-Conference/default.aspx
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Announces-the-Completion-of-Squeeze-Out-Merger-With-VectivBio/default.aspx